650 related articles for article (PubMed ID: 16597510)
41. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
[TBL] [Abstract][Full Text] [Related]
42. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
[TBL] [Abstract][Full Text] [Related]
43. Current status of the Arilvax; yellow fever vaccine.
Barrett AD
Expert Rev Vaccines; 2004 Aug; 3(4):413-20. PubMed ID: 15270646
[TBL] [Abstract][Full Text] [Related]
44. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
[TBL] [Abstract][Full Text] [Related]
45. The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers.
Russell MN; Cetron MS; Eidex RB
J Travel Med; 2006; 13(1):48-9. PubMed ID: 16412108
[No Abstract] [Full Text] [Related]
46. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
47. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
48. Yellow fever vaccine-associated viscerotropic disease.
Rowland M; Plackett TP; Smith R
Mil Med; 2012 Apr; 177(4):467-9. PubMed ID: 22594140
[TBL] [Abstract][Full Text] [Related]
49. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
[TBL] [Abstract][Full Text] [Related]
50. Yellow fever - prevention in travellers.
Neilson AA; Mayer CA
Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751
[TBL] [Abstract][Full Text] [Related]
51. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
Thomas RE; Spragins W; Lorenzetti DL
Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
[TBL] [Abstract][Full Text] [Related]
52. Antibody response to 17D yellow fever vaccine in Ghanaian infants.
Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA; Odoom JK; Nkrumah FK
Bull World Health Organ; 2001; 79(11):1056-9. PubMed ID: 11731813
[TBL] [Abstract][Full Text] [Related]
53. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
[TBL] [Abstract][Full Text] [Related]
54. Short report: Incidence of yellow fever vaccine-associated neurotropic disease.
Guimard T; Minjolle S; Polard E; Fily F; Zeller H; Michelet C; Tattevin P
Am J Trop Med Hyg; 2009 Dec; 81(6):1141-3. PubMed ID: 19996449
[TBL] [Abstract][Full Text] [Related]
55. Prevention of yellow fever in persons traveling to the tropics.
Monath TP; Cetron MS
Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
[TBL] [Abstract][Full Text] [Related]
56. Yellow fever as an endemic/epidemic disease and priorities for vaccination.
Monath TP
Bull Soc Pathol Exot; 2006 Dec; 99(5):341-7. PubMed ID: 17253051
[TBL] [Abstract][Full Text] [Related]
57. Case Report: Fatal Viscerotropic Disease in a Young Woman Following Yellow Fever Vaccination.
Brunaldi MO; Silva RJC; Fabro AT; de Almeida E Araujo DC; Basile-Filho A; Auxiliadora-Martins M; Menegueti MG; Beloddi MI; Alves Esposito DL; Lopes da Fonseca BA
Am J Trop Med Hyg; 2021 Sep; 105(6):1803-1805. PubMed ID: 34491221
[TBL] [Abstract][Full Text] [Related]
58. Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.
Martins Rde M; Pavão AL; de Oliveira PM; dos Santos PR; Carvalho SM; Mohrdieck R; Fernandes AR; Sato HK; de Figueiredo PM; von Doellinger Vdos R; Leal Mda L; Homma A; Maia Mde L
Vaccine; 2014 Nov; 32(49):6676-82. PubMed ID: 24837504
[TBL] [Abstract][Full Text] [Related]
59. A case of yellow fever vaccine-associated disease.
Isenman H; Burns A
N Z Med J; 2012 Feb; 125(1349):92-5. PubMed ID: 22327162
[No Abstract] [Full Text] [Related]
60. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(30):643-5. PubMed ID: 11787575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
